March 21, 2013 at 16:21 PM EDT
Pharma Play Acadia Jumps 24% On Psychosis Study Result
Biopharmaceutical company Acadia rallied 23% Thursday after results of a phase III clinical trial of pimavanserin showed “significant anti-psychotic efficacy” in Parkinson’s disease patients with psychosis. Acadia Pharmaceuticals (ACAD), which has a market value of roughly $651 million, closed up $1.59, or nearly 24%, to $8.24. Pimavanerin is a molecule that acts on seratonin receptors. Parkinson’s [...]
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here